内容摘要：It also includes proposed rules on the rights of bereaved parents to access their children's data if they die, changes to allow NHS trusts to share patient data more easily, and even a 3D underground map of the UK's pipes and cables, aimed at improving the efficiency of roadworks (I told you it was a big bill).

It also includes proposed rules on the rights of bereaved parents to access their children's data if they die, changes to allow NHS trusts to share patient data more easily, and even a 3D underground map of the UK's pipes and cables, aimed at improving the efficiency of roadworks (I told you it was a big bill).

Mr Huxtable has also been finessing the darts of former world champion Price, from Caerphilly county, before he battled it out at the O2 on Thursday."I've never seen focus like that from Gerwyn Price," he said.

"He was a former rugby player who just played socially and he made it into the top 32."He said that's not good enough and when he made it into top 16 he still wasn't happy with that."He was so focused to be the best and to take Gerwyn from being a rugby player to a world champion was a big moment for us."

Mr Huxtable, from Pontypridd, Rhondda Cynon Taf, has completed the majority of his work from Nodor's Bridgend headquarters for about 25 years, but also travels to Kenya where their darts are mass-produced for the retail market.The family-run Nodor group, which Red Dragon Darts is part of, moved production of its darts and dartboards to Kenya after it acquired the Winmau brand about 20 years ago.

The sisal plant grows naturally in the east African country and is the best material for bristle boards, lowering operating costs.

Nodor opened up its own sales and distribution centre in Dallas, Texas in 2023 and now produces 30,000 sets of darts and 20,000 dartboards a week from its factories in Kenya, and employs 1,000 staff.Dr Simon Waters, consultant medical oncologist at Velindre Cancer Centre, said it was a "great opportunity now we've got to this point".

"People have been working on it for a long time. It's great we can now put it in to practice as a standard treatment," he said."We've been using a similar treatment for a smaller group of patients for a few years and that's had quite a lot of issues with side effects and we think this treatment will not only be more effective but also will have fewer issues with side effects.

"It's also applicable to a larger group of patients with this common type of breast cancer."The drug is suitable for those with certain gene mutations that affect up to half of people with hormone receptor positive secondary breast cancer - the most common type, which grows in the presence of oestrogen.